Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;152(1):87-93.
doi: 10.1016/j.ygyno.2018.10.026. Epub 2018 Oct 30.

Validation of the 2018 FIGO cervical cancer staging system

Koji Matsuo  1 , Hiroko Machida  2 , Rachel S Mandelbaum  3 , Ikuo Konishi  4 , Mikio Mikami  2
Affiliations

Validation of the 2018 FIGO cervical cancer staging system

Koji Matsuo et al. Gynecol Oncol. 2019 Jan.

Abstract

Objective: To validate the revised 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer, with a particular focus on stage IB and stage III disease.

Methods: Two retrospective cohort studies were conducted using The Surveillance, Epidemiology, and End Results Program between 1988 and 2014. The stage IB cohort consisted of node-negative FIGO stage IB1 (tumor size <2 cm), IB2 (2-3.9 cm), and IB3 (≥4 cm) cervical cancer. The stage III cohort consisted of FIGO stage IIIA, IIIB, and stage IIIC1 (any pelvic nodal metastasis) cervical cancer. Multivariable analysis was performed for cause-specific survival based on cancer stage.

Results: In the stage IB cohort (n = 8909), stage IB1 tumors were more likely to be adenocarcinoma and low-grade compared to other the groups (P < 0.001). On multivariable analysis, stage IB2 disease was independently associated with a nearly two-fold increased risk of cervical cancer mortality compared to stage IB1 disease (adjusted-hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.62-2.41, P < 0.001). In the stage III cohort (n = 11,733), stage IIIC1 was independently associated with improved cause-specific survival compared to stage IIIB disease (adjusted-HR 0.79, 95%CI 0.74-0.85, P < 0.001). Survival of stage IIIC1 disease significantly differed based on T = stage, (5-year rates: 74.8% for T1, 58.7% for T2, and 39.3% for T3) with a 35.3% difference in absolute survival (P < 0.001).

Conclusion: The 2018 FIGO staging system for cervical cancer is useful to distinguish survival groups; stage IB1 and stage IB2 disease have distinct characteristics and survival outcomes, while survival in stage IIIC1 varies depending on local tumor factors.

Keywords: 2018; Cervical cancer; FIGO; International Federation of Gynecology and Obstetrics; Staging; Validation.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Kaplan-Meier curves based on 2018 FIGO cancer staging system. Log-rank test for P-values. Cause-specific survival is shown for (A) stage IB cervical cancer, (B) stage III cervical cancer, (C) stage IIIC1 cervical cancer, and (D) stage III cervical cancer based on T-stage.
See this image and copyright information in PMC

References

    1. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R, Cancer of the cervix uteri, Int. J. Gynaecol. Obstet 143 (2018) 22–36. - PubMed
    1. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri, Int. J. Gynaecol. Obstet. 125 (2014) 97–98. - PubMed
    1. Waggoner SE, Cervical cancer, Lancet 361 (2003) 2217–2225. - PubMed
    1. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr., Alberts DS, Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, J. Clin. Oncol. 18 (2000) 1606–1613. - PubMed
    1. Singh AK, Grigsby PW, Dehdashti F, Herzog TJ, BA Siegel FDG -PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma, Int. J. Radiat. Oncol. Biol. Phys. 56 (2003) 489–493. - PubMed

Publication types